Angiotensin Inhibition and Gastrointestinal Bleeding Prevention in Patients with Left Ventricular Assist Devices
The VAD Journal · 2020
DOI: 10.11589/vad/e2020623 ↗Kurz gefasst
Fachartikel in der Zeitschrift The VAD Journal, 2020. Verfasst von Phillip Weeks.
Abstract (Originalsprache)
Gastrointestinal bleeding remains a common complication in advanced heart failure patients following implantation of continuous-flow left ventricular assist devices. While the cause is likely multifactorial, development of arterial venous malformations in the gastrointestinal mucosa are a key factor. Inhibition of angiotensin II activity has been postulated to disrupt the signaling that promotes angiogenesis in these patients. We aim to review the theoretical basis for angiotensin receptor blockade, which has been proposed and explore the published evidence regarding this therapy and gastrointestinal bleeding in LVAD patients.
Zitieren
APA
Weeks, P. (2020). Angiotensin Inhibition and Gastrointestinal Bleeding Prevention in Patients with Left Ventricular Assist Devices. The VAD Journal. https://doi.org/10.11589/vad/e2020623
Vancouver
Weeks P. Angiotensin Inhibition and Gastrointestinal Bleeding Prevention in Patients with Left Ventricular Assist Devices. The VAD Journal. 2020. doi:10.11589/vad/e2020623
BibTeX
@article{Weeks2020,
author = {Weeks, Phillip},
title = {Angiotensin Inhibition and Gastrointestinal Bleeding Prevention in Patients with Left Ventricular Assist Devices},
journal = {The VAD Journal},
year = {2020},
doi = {10.11589/vad/e2020623}
}
EUVIMED